|
|
|
|
Study diminshes value of beta blockers in treatment of hypertension
Beta blockers, touted for 3 decades as first-line drugs in the treatment of hypertension, are less than optimum in comparison to other antihypertensive drugs and raise the risk of stroke, according to a meta-analysis published online by The Lancet.
|
| |
More>>
|
|
|
|
|
|
How to get your high-risk patients to the new NCEP goals
Now that the optimal LDL-cholesterol level for patients with coronary heart disease or its risk equivalents is substantially below 100 mg/dL, consider aggressive lipid-lowering strategies in this group. With the advent of more powerful statins, combination therapy, and newer nonstatin agents, you can help a significantly greater proportion of your patients attain their lipid goals.
|
| |
More>>
|
|
|
|
|
|
Who needs lipid-lowering drugs?
Except for quitting smoking, lowering of LDL cholesterol may offer a greater reduction in cardiovascular risk to vulnerable patients than any other strategy now available. Here is a handy reference for your full range of options.
|
| |
More>>
|
|
|
|
|
|
PAD treatment should cover pharmaceutical care
People with lower-extremity peripheral arterial disease (PAD) should get treatment, including pharmaceutical treatment, comparable to that for people with established coronary artery disease. That's according to new, comprehensive guidelines on PAD from the American Heart Association (AHA) and other medical groups.
|
| |
More>>
|
|
|
We subscribe to the HONcode principles of the Health On the Net Foundation